Twitter | Pretraživanje | |
BioPharma Dive
We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma. Sign up here:
13.246
Tweetovi
343
Pratim
9.903
Osobe koje vas prate
Tweetovi
BioPharma Dive 14 h
hopes to replicate its past success in quickly advancing a treatment for Ebola. But, as that experience showed, proving a new antiviral isn't easy.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 15 h
acknowledged the cell therapy developer is worth less than it once thought, cutting the accounting value for research assets it acquired by $800M
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 15 h
With $200M more in bank, also in-licensed an experimental next-generation food allergy therapy from
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 16 h
A yet-to-be-named new company will house 's women's health, biosimilar and legacy drugs, providing space and resources for the pharma's higher-growth businesses.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 4. velj
Anteros Pharmaceuticals is the first company made via a partnership between and biotech accelerator BioMotiv. Its initial targets are liver and lung fibrosis, with one specific focus being IPF.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 4. velj
, and were the most active, collectively raising list prices on some 450 drugs this Jan., according to one Wall Street analyst.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 4. velj
HHS and previously worked together on an experimental Ebola treatment that proved effective in the 2018 outbreak of that disease.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 3. velj
's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 3. velj
With biologics driving growth, is looking to diversify with a $315M purchase that hands it a slate of production sites.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 3. velj
Research into preventive treatments will continue, however, as an NIH leader declared a vaccine "essential" to ending the widespread disease.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 3. velj
will work with Chinese authorities to test its drug remdesivir, while is providing its adjuvant platforms to groups partnered with CEPI.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 31. sij
With $420M in Q4 revenues, 's cystic fibrosis drug Trikafta performed 5x better than expected — and capped off an 8-year growth story for the biotech's CEO.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 31. sij
Too few women and people of color are in executive positions or on the boards of biotech companies, according to a new report from BIO.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 31. sij
Competition is heating up for copycats to 's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive proslijedio/la je tweet
Jacob Bell 31. sij
If you haven't yet, check out 's latest deep dive. After years being all-in on brain drugs, big pharma pulled back. Is a return on the horizon? And, if so, what effects might it have on drug research?
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 30. sij
Spinraza rivals and Tecfidera patent challenges were in the spotlight as provided few details about its planned filing for aducanumab.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 30. sij
's top scientist, however, set low expectations the drug will show a clear benefit.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 29. sij
Biotech execs see a new era of neuroscience advances ahead. But it's hard to pinpoint what would cause pharma to dive back in — and what ripples that would create.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 29. sij
The Third Rock-backed company put an acting executive in place as it repositions for development in gene therapy and regenerative medicine.
Reply Retweet Označi sa "sviđa mi se"
BioPharma Dive 29. sij
Another 100 infants received ' Zolgensma in the fourth quarter, supported by broad insurance coverage and more newborn screening.
Reply Retweet Označi sa "sviđa mi se"